Switch theme
Sign up to access all valuation multiples
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
2018
647
LTM Revenue $17.8M
LTM EBITDA -$208M
-$179M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Autolus Therapeutics has a last 12-month revenue of $17.8M and a last 12-month EBITDA of -$208M.
In the most recent fiscal year, Autolus Therapeutics achieved revenue of $10.1M and an EBITDA of -$202M.
Autolus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Autolus Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.7M | $10.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$157M | -$202M | XXX | XXX | XXX |
| EBITDA Margin | -9233% | -1997% | XXX | XXX | XXX |
| Net Profit | -$149M | -$208M | XXX | XXX | XXX |
| Net Margin | -8766% | -2059% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Autolus Therapeutics's stock price is $1.
Autolus Therapeutics has current market cap of $357M, and EV of -$179M.
See Autolus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$179M | $357M | XXX | XXX | XXX | XXX | $-0.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Autolus Therapeutics has market cap of $357M and EV of -$179M.
Autolus Therapeutics's trades at -10.0x LTM EV/Revenue multiple, and 0.9x LTM EBITDA.
Analysts estimate Autolus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Autolus Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$179M | XXX | XXX | XXX |
| EV/Revenue | -17.7x | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | XXX | XXX |
| P/E | -1.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAutolus Therapeutics's NTM/LTM revenue growth is 248%
Autolus Therapeutics's revenue per employee for the last fiscal year averaged $16K, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Autolus Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Autolus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Autolus Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 496% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1997% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1749% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $16K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1368% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2367% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Autolus Therapeutics acquired XXX companies to date.
Last acquisition by Autolus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Autolus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Autolus Therapeutics founded? | Autolus Therapeutics was founded in 2018. |
| Where is Autolus Therapeutics headquartered? | Autolus Therapeutics is headquartered in United States of America. |
| How many employees does Autolus Therapeutics have? | As of today, Autolus Therapeutics has 647 employees. |
| Who is the CEO of Autolus Therapeutics? | Autolus Therapeutics's CEO is Dr. Christian Itin, PhD.. |
| Is Autolus Therapeutics publicy listed? | Yes, Autolus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Autolus Therapeutics? | Autolus Therapeutics trades under AUTL ticker. |
| When did Autolus Therapeutics go public? | Autolus Therapeutics went public in 2018. |
| Who are competitors of Autolus Therapeutics? | Similar companies to Autolus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Autolus Therapeutics? | Autolus Therapeutics's current market cap is $357M |
| What is the current revenue of Autolus Therapeutics? | Autolus Therapeutics's last 12-month revenue is $17.8M. |
| What is the current EBITDA of Autolus Therapeutics? | Autolus Therapeutics's last 12-month EBITDA is -$208M. |
| What is the current EV/Revenue multiple of Autolus Therapeutics? | Current revenue multiple of Autolus Therapeutics is -10.0x. |
| What is the current EV/EBITDA multiple of Autolus Therapeutics? | Current EBITDA multiple of Autolus Therapeutics is 0.9x. |
| What is the current revenue growth of Autolus Therapeutics? | Autolus Therapeutics revenue growth between 2023 and 2024 was 496%. |
| Is Autolus Therapeutics profitable? | Yes, Autolus Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
